Gilead Sciences, Inc. (GILD)
| Market Cap | 139.85B |
| Revenue (ttm) | 28.86B |
| Net Income (ttm) | 6.31B |
| Shares Out | 1.24B |
| EPS (ttm) | 5.01 |
| PE Ratio | 22.49 |
| Forward PE | 13.40 |
| Dividend | $3.16 (2.80%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 4,408,895 |
| Open | 112.90 |
| Previous Close | 112.97 |
| Day's Range | 111.28 - 113.30 |
| 52-Week Range | 77.74 - 121.83 |
| Beta | 0.35 |
| Analysts | Buy |
| Price Target | 115.68 (+2.64%) |
| Earnings Date | Aug 7, 2025 |
About GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for GILD stock is "Buy." The 12-month stock price target is $115.68, which is an increase of 2.64% from the latest price.
News
Gilead Sciences: HIV Leadership Outshines Decline In COVID-19 Drug Sales
Despite retail investors' cautious attitude toward Gilead Sciences, it once again beat analysts' expectations by a wide margin. In my estimation, Gilead's main star remains Biktarvy, which leaves comp...
EU approves Gilead's new injection for preventing HIV
The European Commission has granted marketing authorization for Gilead Sciences' twice-yearly injection for preventing HIV infection, the company said on Tuesday.
European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo® (lenacapavir)—the company's...
Gilead unit to acquire cell therapy developer Interius for $350 million
Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for $350 million in cash to advance CAR T-cell cancer therapies that are deliver...
CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans
CVS Health Inc. CVS said it will not add Gilead Sciences Inc.'s GILD new HIV prevention drug Yeztugo to its commercial plans.
Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform
SANTA MONICA, Calif. & PHILADELPHIA--(BUSINESS WIRE)--Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held company developing in vivo CAR therapeutics.
From Stagnation To Surge: Gilead Sciences Is Entering Its Next Growth Wave
Gilead Sciences remains a long-term Buy due to solid quarterly results, raised guidance, and continued strength in its HIV portfolio, especially Biktarvy. The recent launch of Yeztugo and a robust HIV...
Exclusive: CVS holds off adding Gilead's new HIV prevention shot to drug coverage lists
CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite the medic...
Gilead Sciences to Present at Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Cantor Global Healthc...
Our Top 10 High Growth Dividend Stocks - August 2025
The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rat...
Final Trade: BSY, GDX, MNDY, GILD
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Gilead Sciences shares soar; analysts lift targets on HIV strength and Yeztugo outlook
Gilead Sciences' stock surged more than 8% on Friday, as its latest earnings drew the consensus from Wall Street that the company's HIV franchise is not only holding firm but expanding, with its new p...
Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears
Gilead Sciences GILD announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday.
These Stocks Are Moving Most Today: Trade Desk, Expedia, Pinterest, Twilio, Gilead Sciences
A flurry of company earnings led to big stock moves early Friday.
Gilead Sciences, Inc. (GILD) Q2 2025 Earnings Call Transcript
Gilead Sciences, Inc. (NASDAQ:GILD) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Andrew D. Dickinson - Chief Financial Officer Daniel P.
Gilead Sciences Q2: The New Drug That Could Change Everything
Gilead Sciences, Inc.'s HIV franchise, led by Biktarvy, ensures stable cash flows through 2033, providing long-term visibility and a strong competitive advantage. The launch of Yeztugo, a biannual PrE...
Gilead posts flat quarterly profit, raises full-year outlook
Gilead Sciences on Thursday reported flat quarterly earnings on slightly higher revenue and raised its full-year financial outlook due largely to better-than-expected sales of HIV drugs.
Gilead Sciences Announces Second Quarter 2025 Financial Results
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its second quarter 2025 results of operations. “This was a very successful second quarter for Gil...
How To Earn $500 A Month From Gilead Sciences Stock Ahead Of Q2 Earnings
Gilead Sciences, Inc. GILD will release earnings results for the second quarter, after the closing bell on Thursday, Aug. 7.
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.
President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
Trump pressures 17 pharma CEOs to cut US drug prices
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...